[Cited FineTest ELISA Kit] Current Research on HER2 Positive Breast Cancer Treatment

FineTest ELISA kit contributes to the research on HER2 positive breast cancer treatment. The immunoassay is designed to measure TNF-α and IFN-γ level in supernatant.

Article Title: Molecular Characterization and Classification of HER2-Positive Breast Cancer Inform Tailored Therapeutic Strategies
Journal Title: Cancer Research
DOI: 10.1158/0008-5472.CAN-23-4066
IF: 12.5
PMID: 39186675

Abstract:   Recent studies have suggested that HER2-positive breast cancer is a group of heterogeneous diseases with different sensitivities to standard treatment regimens. Revealing the molecular heterogeneity of HER2-positive breast cancer could potentially enable more precise treatment strategies. In this study, we performed multiomics profiling and identified four transcriptome-based subtypes. The classical HER2 (HER2-CLA) subtype comprised 28.3% of the samples and displayed high ERBB2 activation and significant benefit from anti-HER2 therapy. The immunomodulatory (HER2-IM) subtype (20%) featured an immune-activated microenvironment, potentially suitable for de-escalated treatment and immunotherapy. The luminal-like (HER2-LUM) subtype (30.6%) possessed similar molecular features of hormone receptor–positive HER2-negative breast cancer, suggesting endocrine therapy and CDK4/6 inhibitors as a potential therapeutic strategy. Lastly, the basal/mesenchymal-like (HER2-BM) subtype (21.1%) had a poor response to current dual HER2-targeted therapy and could potentially benefit from tyrosine kinase inhibitors. The molecular characteristics and clinical features of the subtypes were further explored across multiple cohorts, and the feasibility of the proposed treatment strategies was validated in patient-derived organoid and patient-derived tumor fragment models. This study elucidates the molecular heterogeneity of breast cancer and paves the way for a more tailored treatment.

Keywords:  Breast Cancer, Heterogeneous Disease, Cancer Immunotherapy, Biomarkers, Gene Expression, Drug Therapy, Tumor Microenvironment

Immunoassay

Validated Image

Figure Source: Cancer Res. 2024 Nov 4;84(21):3669-3683. doi: 10.1158/0008-5472.CAN-23-4066.